Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

NCT02381886 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02381886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02381886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 6, 2015
Completion date
October 31, 2030
Enrollment
166 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies that harbor idhr132 mutations